参考文献：1. Changsong QI, Chang Liu, Jifang Gong,etc.Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.[J].2024 ASCO.2.文 凤，李 秋.CAR-T在消化道实体瘤治疗中的研究进展与展望[J].延安大学...
最新数据：多线治疗无效后，CAR-T为患者带来71.4%临床获益率 摘要356：CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial.研究背景：自体抗CLDN18.2（CLDN18.2）CAR-T细胞，即satri-cel（CT...
近日，斯坦福大学医学院David B. Miklos及Crystal L. Mackall团队在Nature Medicine发表题为CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial 的研究论文，报道了靶向CD19和CD22的双位点特异性CAR T细胞 (CD19-22.BB....
Chávez, J.C., Bachmeier, C.A. and Kharfan‐Dabaja, M.A. (2019) 'CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products,' Therapeutic Advances in Hematology, 10, p. 204062071984158. https://doi.org/...
2024年6月3日上午,北京大学肿瘤医院齐长松教授在ASCO年会“新兴疗法——免疫治疗”口头报告专场中就“Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial”研究作了精彩报告。同一天,齐长松教授第一作者,沈琳教授团...
通用的“现货型”CAR-T疗法是当前被受关注的解决策略。“现货型”CAR-T疗法由健康志愿者捐赠T细胞后改造为CAR-T,并通过基因编辑敲除内源性T细胞受体和来自健康供体的T细胞表面的人类白细胞抗原(HLA),从而降低异体细胞输入带来的免疫排斥和移植物抗宿主病风险。
相关研究结果于2023年1月23日在线发表在Nature Medicine期刊上,论文标题为“Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results”。 骨髓瘤发生于骨髓中的浆细胞。在这项新的研究中,这些作者给患者提供了不同数量的捐赠的CAR-T细胞,作为骨髓瘤I...
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. https://doi.org/10.1038/s41591-023-02404-6 ...
摘要356:CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial. 研究背景:自体抗CLDN18.2(CLDN18.2)CAR-T细胞,即satri-cel(CT041),被开发用于治疗实体肿瘤。此文报告了针对胃癌/胃食管交界处癌(GC...
1.Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results 2.Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells - PMC (nih.gov) 3.CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer - PMC (nih.gov)...